Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of BB3 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery

Next Previous
Trial Profile

A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of BB3 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Terevalefim (Primary)
  • Indications Acute kidney injury
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GUARD
  • Sponsors Angion Biomedica; Elicio Therapeutics

    • Most Recent Events

    • 01 Jun 2023 According to an Elicio Therapeutics media release, Angion Biomedica merged with the Elicio Therapeutics and the combined company is called as Elicio Therapeutics.
    • 02 Aug 2022 According to a CSL Vifor media release, Vifor Pharma has been acquired by CSL and renamed to CSL Vifor.
    • 10 Dec 2021 Results presented in an Angion Biomedica and Vifor Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top